Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.
Apr, 2018
David R. Snydman, Laura A. McDermott, Nilda V. Jacobus, Kathryn Kerstein, Trudy H. Grossman, Joyce A. Sutcliffe
Antimicrobial Agents and Chemotherapy: 2018 Apr 26;62(5). pii: e02206-17. doi: 10.1128/AAC.02206-17. | 29483114
Abstract
The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.